[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.98.97. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Urology
    March 31, 2020

    Geographic Distribution of Racial Differences in Prostate Cancer Mortality

    Author Affiliations
    • 1Division of Urological Surgery, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts
    • 2Center for Surgery and Public Health, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts
    • 3James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
    • 4Department of Radiation Oncology, Harvard Medical School, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, Massachusetts
    • 5Lank Center for Genitourinary Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts
    JAMA Netw Open. 2020;3(3):e201839. doi:10.1001/jamanetworkopen.2020.1839
    Key Points español 中文 (chinese)

    Question  How do race-based disparities in prostate cancer outcomes differ geographically within the US?

    Findings  In this cohort study of 229 771 men in 17 geographic registries within the Surveillance, Epidemiology, and End Results database, black men had a higher risk of mortality overall compared with white men. The greatest race-based survival difference was seen in men with low-risk prostate cancer in the Atlanta, Georgia, registry, where mortality risk among black men was increased more than 5-fold.

    Meaning  These findings suggest that race-based survival differences in prostate cancer vary regionally, which may allow for targeted interventions to mitigate these disparities.

    Abstract

    Importance  While racial disparities in prostate cancer mortality are well documented, it is not well known how these disparities vary geographically within the US.

    Objective  To characterize geographic variation in prostate cancer–specific mortality differences between black and white men.

    Design, Setting, and Participants  This cohort study included data from 17 geographic registries within the Surveillance, Epidemiology, and End Results (SEER) database from January 1, 2007, to December 31, 2014. Inclusion criteria were men 18 years and older with biopsy-confirmed prostate cancer. Men missing data on key variables (ie, cancer stage, Gleason grade group, prostate-specific antigen level, and survival follow-up data) were excluded. Analysis was performed from September 5 to December 25, 2018.

    Exposure  Patient SEER-designated race (ie, black, white, or other).

    Main Outcomes and Measures  Fine and Gray competing-risks regression analyses were used to evaluate the difference in prostate-cancer specific mortality between black and white men. A stratified analysis by Gleason grade group was performed stratified as grade group 1 and grade groups 2 through 5.

    Results  The final cohort consisted of 229 771 men, including 178 204 white men (77.6%), 35 006 black men (15.2%), and 16 561 men of other or unknown race (7.2%). Mean (SD) age at diagnosis was 64.9 (8.8) years. There were 4773 prostate cancer deaths among white men and 1250 prostate cancer deaths among black men. Compared with white men, black men had a higher risk of mortality overall (adjusted hazard ratio [AHR], 1.39 [95% CI, 1.30-1.48]). In the stratified analysis, there were 4 registries in which black men had worse prostate cancer-specific survival in both Gleason grade group 1 (Atlanta, Georgia: AHR, 5.49 [95% CI, 2.03-14.87]; Greater Georgia: AHR, 1.88 [95% CI, 1.10-3.22]; Louisiana: AHR, 1.80 [95% CI, 1.06-3.07]; New Jersey: AHR, 2.60 [95% CI, 1.53-4.40]) and Gleason grade groups 2 through 5 (Atlanta: AHR, 1.88 [95% CI, 1.46-2.45]; Greater Georgia: AHR, 1.29 [95% CI, 1.07-1.56]; Louisiana: AHR, 1.28 [95% CI, 1.07-1.54]; New Jersey: AHR, 1.52 [95% CI, 1.24-1.87]), although the magnitude of survival difference was lower than for Gleason grade group 1 in each of these registries. The greatest race-based survival difference for men with Gleason grade group 1 disease was in the Atlanta registry.

    Conclusions and Relevance  These findings suggest that population-level differences in prostate cancer survival among black and white men were associated with a small set of geographic areas and with low-risk prostate cancer. Targeted interventions in these areas may help to mitigate prostate cancer care disparities at the national level.

    ×